Hypercholesterolemia Drugs Market Size, Share, Global Insights and Analysis
- Submitted by: Marketreport
- Views: 58
- Category: Other
- Date Submitted: 08/03/2016 03:03 AM
- Pages: 5
- Report this Essay
Summary
Technavio Announces the Publication of its Research Report Global Hypercholesterolemia Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the global hypercholesterolemia drugs market: AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, and Sanofi.
Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, and Zydus Cadila.
Browse full report with TOC@ https://marketreportscenter.com/reports/344159/global-hypercholesterolemia-drugs-market-2016-2020
Commenting on the report, an analyst from Technavios team said: One of the major trends for market growth will be the increased use of combination therapies. Combinations of drugs are often used to treat conditions and they are mostly useful in managing lipid abnormalities. Combination therapies have advantages over monotherapies in terms of efficacy and a reduced incidence of adverse effects. Further, combination therapies have lesser manufacturing costs compared to the costs of manufacturing monotherapies administered concurrently, simpler logistics of distribution, and improved patient compliance by reducing the pill burden. Combination therapy in fixed dose combinations containing a statin and another lipid-lowering drug is available in the market.
According to the report, one of...
Technavio Announces the Publication of its Research Report Global Hypercholesterolemia Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the global hypercholesterolemia drugs market: AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, and Sanofi.
Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, and Zydus Cadila.
Browse full report with TOC@ https://marketreportscenter.com/reports/344159/global-hypercholesterolemia-drugs-market-2016-2020
Commenting on the report, an analyst from Technavios team said: One of the major trends for market growth will be the increased use of combination therapies. Combinations of drugs are often used to treat conditions and they are mostly useful in managing lipid abnormalities. Combination therapies have advantages over monotherapies in terms of efficacy and a reduced incidence of adverse effects. Further, combination therapies have lesser manufacturing costs compared to the costs of manufacturing monotherapies administered concurrently, simpler logistics of distribution, and improved patient compliance by reducing the pill burden. Combination therapy in fixed dose combinations containing a statin and another lipid-lowering drug is available in the market.
According to the report, one of...